Xtant Medical Holdings, Inc. (XTNT) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XTNT Revenue Growth
Revenue Breakdown (FY 2024)
XTNT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
XTNT Revenue Analysis (2013–2024)
As of May 8, 2026, Xtant Medical Holdings, Inc. (XTNT) generated trailing twelve-month (TTM) revenue of $133.1 million, reflecting strong growth of +19.0% year-over-year. The most recent quarter (Q3 2025) recorded $33.3 million in revenue, down 6.1% sequentially.
Looking at the longer-term picture, XTNT's 5-year compound annual growth rate (CAGR) stands at +12.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $117.3 million in 2024, representing a new all-time high.
Revenue diversification analysis shows XTNT's business is primarily driven by Orthobiologics (57%), Spinal Implant (42%), and License Revenue (1%). With over half of revenue concentrated in Orthobiologics, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ATEC (-7.4% YoY), NVCR (+8.5% YoY), and OSPN (+1.7% YoY), XTNT has underperformed the peer group in terms of revenue growth. Compare XTNT vs ATEC →
XTNT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XTNTCurrent | $133M | +19.0% | +12.6% | -10.3% | |
 ATEC | $764M | -7.4% | +39.5% | -10.7% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 OSPN | $243M | +1.7% | +2.4% | 20.6% | |
 GMED | $2.9B | +23.5% | +30.1% | 16.3% | |
 OSIS | $1.7B | +7.0% | +8.0% | 12.7% |
XTNT Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $117.3M | +28.4% | $68.2M | 58.2% | $-12,074,000 | -10.3% |
| 2023 | $91.3M | +57.5% | $55.5M | 60.8% | $-10,158,000 | -11.1% |
| 2022 | $58.0M | +4.9% | $32.1M | 55.4% | $-6,755,000 | -11.7% |
| 2021 | $55.3M | +3.6% | $32.5M | 58.8% | $-3,854,000 | -7.0% |
| 2020 | $53.3M | -17.5% | $34.4M | 64.5% | $-751,000 | -1.4% |
| 2019 | $64.7M | -10.4% | $42.5M | 65.7% | $-2,354,000 | -3.6% |
| 2018 | $72.2M | -12.6% | $43.5M | 60.2% | $-60,078,000 | -83.2% |
| 2017 | $82.6M | -8.2% | $50.1M | 60.6% | $-37,834,321 | -45.8% |
| 2016 | $90.0M | +51.7% | $62.3M | 69.2% | $-7,545,264 | -8.4% |
| 2015 | $59.3M | +68.0% | $39.1M | 65.9% | $-12,078,101 | -20.4% |
See XTNT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XTNT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XTNT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXTNT — Frequently Asked Questions
Quick answers to the most common questions about buying XTNT stock.
Is XTNT's revenue growth accelerating or slowing?
XTNT revenue is accelerating at +19.0% year-over-year, exceeding the 5-year CAGR of +12.6%. TTM revenue reached $133M. Growth momentum has increased versus prior periods.
What is XTNT's long-term revenue growth rate?
Xtant Medical Holdings, Inc.'s 5-year revenue CAGR of +12.6% reflects the sustained expansion pattern. Current YoY growth of +19.0% is above this long-term average.
How is XTNT's revenue distributed by segment?
XTNT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.